Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 6/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 3/20 | 0.42 |
| ▸ | GRK3 | P35626 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889478 | 1.00 | MEN1 (0.46) | MEN1GAAKMT2AMAPK1FOLH1 | |
| SCHEMBL4598833 | 0.86 | CA1 (0.47) | MEN1GAAKMT2AFOLH1C3AR1 | |
| SCHEMBL4598827 | 0.86 | CA1 (0.47) | MEN1GAAKMT2AFOLH1C3AR1 | |
| SCHEMBL4889077 | 0.86 | FOLH1 (0.54) | MEN1KMT2AFOLH1C3AR1GRK2 | |
| SCHEMBL4889060 | 0.86 | FOLH1 (0.54) | MEN1KMT2AFOLH1C3AR1GRK2 | |
| SCHEMBL4889214 | 0.83 | SMN1; SMN2 (0.51) | MEN1GAAKMT2AMAPK1GRK2 | |
| SCHEMBL4889227 | 0.83 | SMN1; SMN2 (0.51) | MEN1GAAKMT2AMAPK1GRK2 | |
| SCHEMBL4600219 | 0.83 | MTNR1A (0.47) | MEN1KMT2AC3AR1HDAC1GRK2 | |
| SCHEMBL4739946 | 0.83 | GRK2 (0.47) | MAPK1HDAC1GRK2GRK3ROCK2 | |
| SCHEMBL4739940 | 0.83 | GRK2 (0.47) | MAPK1HDAC1GRK2GRK3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MEN1 4687/4885GAA 617/4885KMT2A 3406/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MEN1 3230/4885GAA 139/4885KMT2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.